Short Bowel Syndrome Market Size, Share, Growth, Trends, Analysis and Forecast 2017 to 2025

According to the latest report published by Credence Research, Inc. the short bowel syndrome market was estimated at US$ 315.1 million in 2016 and is expected to reach US$ 2.901.0 million by 2025, rising to CAGR by 27.5 per cent from 2017 to 2025.

Market Insights       

Short bowel syndrome is a complex disease group that arises due to a small and/or large intestine failure. Individuals with short bowel syndrome show poor absorption of nutrients such as milk, fats, carbohydrates, vitamins, minerals and other essential elements contributing to obesity, weight loss. However in some cases, short bowel syndrome can lead to serious, life-threatening and disabling complications. There is no particular cure for this disorder however the surgical removal (resection) of half or more of the small intestine is successful. Short bowel syndrome can lead to Crohn's disease, illness, or small intestine trauma. Such complications make a significant contribution to the development of the market for short bowel syndrome. On the basis of drugs, the market is divided into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market for drugs in the short bowel syndrome market as it is marketed in the U.S. and Europe under the brand names Gattex and Revestive in Europe and other international markets. Drugs currently hold the status of orphan drugs, and the exclusivity of drugs in the treatment of short bowel syndrome would continue to generate huge revenues during the forecast period.

Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/short-bowel-syndrome-market

North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000-7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.

Market Competition Assessment:

The short bowel syndrome market comprises large number of pharmaceutical giants operating in the market. Shire holds the largest market share in the short bowel syndrome market. The companies include Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.

Key Market Movements:

–  Growing prescriptions of Gattex and Revestive in U.S. and Europe respectively is boosting the growth of the short bowel syndrome market.

– Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. and Europe.

You can get the sample copy of this research by Credence Research here: https://www.credenceresearch.com/sample-request/58584

Global Short Bowel Syndrome Market is Expected to Reach worth USD 2.9 Mn By 2025 | Credence Research

According to the latest report published by Credence Research, Inc. “Short Bowel Syndrome Market — (Drug Type — GLP-2, Glutamine, Growth Hormone and Other Drugs): Market Growth, Future Prospects and Competitive Analysis, 2017–2025,” the short bowel syndrome market was valued at US$ 315.1 million in 2016 and is anticipated to achieve US$ 2.901.0 million by 2025, increasing to CAGR by 27.5 per cent from 2017 to 2025.

Browse the full report at https://www.credenceresearch.com/report/short-bowel-syndrome-market

Market Insights

Short bowel syndrome is a complex disease group that happens owing to a tiny and/or big intestine malfunction. Individuals with short bowel syndrome display bad absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other essential components leading to malnutrition, weight loss. In some instances, however, short bowel syndrome can lead to serious, debilitating and life-threatening complications. There is no specific cure for this disease but the surgical removal (resection) of half or more of the small intestine is efficient. Short bowel syndrome can lead to Crohn’s disease, injury or small intestine trauma. Such complications make a important contribution to the development of the market for short bowel syndrome. On the basis of drugs, the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 is presently the biggest drug market in the short bowel syndrome industry as it is sold in the U.S. and Europe under the brand names Gattex and Revestive in Europe and other global markets. Drugs presently have orphan drug status, and the exclusivity of drugs in the therapy of short bowel syndrome would further generate enormous revenues during the forecast period.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58584

North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000–7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.

Market Competition Assessment:

The short bowel syndrome market comprises large number of pharmaceutical giants operating in the market. Shire holds the largest market share in the short bowel syndrome market. The companies include Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.

Key Market Movements:
- Growing prescriptions of Gattex and Revestive in U.S. and Europe respectively is boosting the growth of the short bowel syndrome market.
- Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. and Europe.

By Drug Type
GLP-2
Glutamine
Growth Hormone
Others

By Geography Segment
North America
Europe
Asia Pacific (APAC)
Middle East & Africa (MEA)
Latin America

Do Inquiry before buying report at https://www.credenceresearch.com/inquiry-before-buying/58584

Short Bowel Syndrome Market Size, Share, Growth, Trends, and Opportunities and Forecast 2018-2026

According to the latest report published by Credence Research, Inc. “Short Bowel Syndrome Market – (Drug Type – GLP-2, Glutamine, Growth Hormone and Other Drugs): Market Growth, Future Prospects and Competitive Analysis, 2017-2025,” the market was valued at US$ 315.1 Mn in 2016, and is expected to reach US$ 2,901.0 Mn by 2025, expanding at a CAGR of 27.5% from 2017 to 2025.
The report titled “Global Short Bowel Syndrome Market: 2018 Edition” examines the potential possibilities and significant trends in the Short Bowel Syndrome industry. The report provides a detailed analysis of the global Short Bowel Syndrome Market including the regional markets of North America, Europe, and the Asia Pacific. It focuses on the Short Bowel Syndrome Markets of the U.S., Canada, UK, India, and Australia. The report also assesses the commercial and residential service sector in the Short Bowel Syndrome industry.
Browse Full Report With Toc: https://www.credenceresearch.com/report/short-bowel-syndrome-market
Further, Porter’s Five Forces Analysis has been done for the global Short Bowel Syndrome industry. In-depth analysis of key market growth drivers and challenges and the major observable trends in the global Short Bowel Syndrome Market are also given in the report. The growth of the market has been projected taking into consideration various aspects like previous growth patterns, the current trends, the growth drivers, challenges and environmental conditions.
Region/Country Coverage

• North America- United States & Canada
• Europe- United Kingdom
• APAC- India & Australia

Get here the sample in PDF: https://www.credenceresearch.com/sample-request/58584
Company Coverage:
Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.
Executive summary: 
Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drug the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market in terms of drug in the short bowel syndrome market as it is marketed in U.S. and Europe under the brand name Gattex and Revestive in Europe and other international market. The drugs currently holds the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the global Short Bowel Syndrome Market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global Short Bowel Syndrome Market
- Leading company profiles reveal details of key Short Bowel Syndrome Market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global Short Bowel Syndrome Market with 7-year forecasts
Reasons to buy
- What was the size of the global Short Bowel Syndrome Market by value in 2017?
- What will be the size of the global Short Bowel Syndrome Market in 2026?
- What factors are affecting the strength of competition in the global Short Bowel Syndrome Market?
- How has the market performed over the last five years?
- What are the main segments that make up the global Short Bowel Syndrome Market?
Request Customization: https://www.credenceresearch.com/request-for-customization/58584
Our Blog: http://www.technicaltop.com/
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com
Follow Us: Twitter
LinkedIn @ https://us.linkedin.com/company/credenceresearch

Short Bowel Syndrome Market Size, Share, Growth, Outlook, Analysis and Forecast 2017 To 2025: Credence Research

According to the latest report published by Credence Research, Inc. “Short Bowel Syndrome Market – (Drug Type – GLP-2, Glutamine, Growth Hormone and Other Drugs): Market Growth, Future Prospects and Competitive Analysis, 2017-2025,” the market was valued at US$ 315.1 Mn in 2016, and is expected to reach US$ 2,901.0 Mn by 2025, expanding at a CAGR of 27.5% from 2017 to 2025.

Browse the full report Short Bowel Syndrome Market: Market Growth, Future Prospects and Competitive Analysis, 2017-2025 at http://www.credenceresearch.com/report/short-bowel-syndrome-market

Market Insights                                                  

Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drug the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market in terms of drug in the short bowel syndrome market as it is marketed in U.S. and Europe under the brand name Gattex and Revestive in Europe and other international market. The drugs currently holds the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period.

North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000-7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.

Market Competition Assessment:

The short bowel syndrome market comprises large number of pharmaceutical giants operating in the market. Shire holds the largest market share in the short bowel syndrome market. The companies include Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.

Key Market Movements:

-  Growing prescriptions of Gattex and Revestive in U.S. and Europe respectively is boosting the growth of the short bowel syndrome market.

- Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. and Europe.

Download Free Sample: http://www.credenceresearch.com/sample-request/58584

Browse the full report Short Bowel Syndrome Market: Market Growth, Future Prospects and Competitive Analysis, 2017-2025 at http://www.credenceresearch.com/report/short-bowel-syndrome-market

About Us: 

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com